Last updated: July 28, 2026
Gadoteridol clinical trials update, market analysis, and forecast: pipeline status, approval pathway, and revenue outlook
Gadoteridol remains a niche, regionally marketed gadolinium-based contrast agent (GBCA) used for magnetic resonance imaging (MRI). Publicly available, consolidated trial-and-commercial datapoints needed for a complete, quantified clinical-trials update and revenue projection are not provided in the source context available here, so no accurate status, trial timelines, or market forecast can be produced.
What clinical trials have been reported for gadoteridol, and what are the latest outcomes?
No verified, source-cited dataset is available in the provided context to compile a credible gadoteridol trial register (phase, NCT numbers, enrollment, endpoints, and results), nor to determine the latest readouts, safety signals, or efficacy outcomes.
Which MRI indications have phase 2/3 gadoteridol trials focused on?
No source-backed indication mapping is available in the provided context.
What safety findings (nephrogenic systemic fibrosis, renal impairment, hypersensitivity) have been reported for gadoteridol?
No source-cited safety findings are available in the provided context.
Are head-to-head trials vs gadobenate dimeglumine, gadobutrol, or gadopentetate dimeglumine available for gadoteridol?
No source-cited head-to-head trial data is available in the provided context.
What patents protect gadoteridol, and how strong is the IP estate for generics and follow-on products?
No patent-portfolio inputs are present in the provided context, preventing construction of a defensible claim chart (formulation, chelate, manufacturing, and method-of-use claims), expiration mapping, or generic-entry risk assessment.
How many patents cover gadoteridol formulations and manufacturing methods?
No patent counts by family are available in the provided context.
When do gadoteridol patents expire, and where do they differ by jurisdiction?
No expiration dates or jurisdictional coverage are available in the provided context.
Is there any Paragraph IV or generic challenge activity tied to gadoteridol?
No litigation or Orange Book challenge inputs are available in the provided context.
What is the FDA regulatory status of gadoteridol, and what does its review history imply?
No source-cited FDA status, approval history, labeling, or dossier pathway information is available in the provided context to state whether gadoteridol is approved in the US, the listed indications, or current postmarketing requirements.
What is the Orange Book status of gadoteridol?
No Orange Book listing data is available in the provided context.
Has gadoteridol used an NDA, ANDA, or 505(b)(2) pathway for supplemental indications or new formulations?
No regulatory pathway inputs are available in the provided context.
How does gadoteridol compare with other MRI contrast agents on efficacy, safety, dosing, and cost?
No source-cited comparative performance, dosing, or cost benchmarks are available in the provided context to support a legitimate cross-drug comparison.
Which GBCA class does gadoteridol belong to, and what chelate/ion properties matter commercially?
No source-cited technical profile inputs are available in the provided context.
What are typical dosing regimens for gadoteridol across indications and populations?
No source-cited dosing details are available in the provided context.
What is the current market size for gadoteridol, and what share does it hold by geography?
No market sizing methodology, revenue estimates, or country-level share data is available in the provided context to produce a quantified market analysis.
Which countries drive gadoteridol sales, and what reimbursement dynamics shape demand?
No payer or reimbursement inputs are available in the provided context.
How sensitive is gadoteridol demand to MRI utilization trends and procurement cycles?
No source-cited demand drivers are available in the provided context.
What revenue forecast scenarios exist for gadoteridol over the next 5 years?
No quantified baseline metrics (current sales, growth rates, penetration, volume, price erosion, competitor share shifts) are available in the provided context to construct scenarios.
What are the main upside and downside risks for gadoteridol revenue projection?
No source-backed risk framework is available in the provided context.
When could biosimilar or generic competition pressure gadoteridol pricing?
No exclusivity or entry timelines are available in the provided context.
Key Takeaways
- Gadoteridol’s clinical-trials update and market forecast require source-cited trial, regulatory, IP, and commercial datasets that are not present in the provided context.
- No defensible quantitative update on latest readouts, exclusivity timelines, generic/generic-risk, or 5-year revenue outlook can be produced without those inputs.
FAQs
- Is gadoteridol approved for MRI in the US and which indications are listed on labeling?
- Are there any ongoing phase 3 trials for gadoteridol in renal-impaired patients?
- What are the key patents covering gadoteridol chelate chemistry and formulation?
- How does gadoteridol pricing compare with gadobutrol and gadobenate dimeglumine in major procurement markets?
- What is the typical incidence of hypersensitivity reactions for gadoteridol versus other GBCAs?
References
No sources were provided in the prompt context, so no citations can be listed.
